Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the modules
  7. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Canadian Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Media Room

Contact us

Sanofi Canada

2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3

Media inquiries

514-856-3860
Toll-free: 1-877-904-2667

Catherine Cunningham

Manager, Corporate and
Brand Communications
514-956-6120

General inquiries

514-956-6200
1-800-363-6364

Press Releases

Pursuing Innovation to Benefit the Health of Canadians

Sanofi Canada Recognized as One of Canada’s Top R&D Investors

Jan 27, 2017

Montreal, Quebec – January 26, 2017 – Sanofi Canada is pleased to announce that it ranks among Canada’s Top 100 Corporate Research and Development (R&D) Spenders, according to a new report published by Research Infosource Inc.

The Laval-based healthcare partner invested $133.3 million in R&D in fiscal 2015, ranking third amongst Canadian companies for overall R&D spend as a percentage of revenue (19.2%). Sanofi Canada’s investment, which is focused on developing innovative therapies in areas such as oncology, diabetes  and cardiology, also establishes the company as one the top three R&D spenders within the Canadian healthcare industry, and figures among the top 25 in the country.

“Sanofi Canada is honoured to be recognized for its longstanding commitment to supporting a robust and dynamic research and development community in Canada,” said Niven Al-Khoury, General Manager at Sanofi Canada. “The scientific community is at a pivotal point in Canada, at a time when our healthcare needs have never been greater.  Being recognized as one of the country’s top investors in R&D speaks to our commitment to providing patients with innovative treatments, and innovation must remain a priority if we are to empower life both today and in the future.”

Sanofi’s broad range of R&D priorities include diabetes, cardiology, vaccines, rare diseases and oncology.

About Sanofi – www.sanofi.ca

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi entities in Canada include the Diabetes and Cardiovascular Care Business Unit, the General Medicines and Established Products Business Unit, Sanofi Pasteur (vaccines), Sanofi Genzyme (specialty care) and Sanofi Consumer Health. Together they employ close to 1,900 people. In 2015 Sanofi companies invested $133.3 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

 

-30-

 

To coordinate an interview or for more information:

Catherine R. Cunningham    
Sanofi Canada 
Tel: 514-956-6120  
Cell: 514-713-1634  
catherine.cunningham@sanofi.com       

Kristin Gable
NATIONAL Public Relations
Tel: 514-843-2378
Cell: 514-209-0984
kgable@national.ca